Morgan Stanley upgraded Takeda (TAK) to Overweight from Equal Weight with a price target of 5,500 yen, up from 4,300 yen. The company does not have any big patents expiring soon that would significantly affect its earnings, and has established a stable portfolio with plasma-derived therapies, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Takeda Canada says Health Canada expands marketing authorization for HyQvia
- Mirum Pharmaceuticals partner Takeda receives approval for Livmarli in Japan
- Harmony Biosciences CCO Jeffrey Dierks steps down, Adam Zaeske succeedsTakeda
- Takeda Announces Share Repurchase Program for February 2025
- Takeda announces EMA approval for Takhzyro two mL pre-filled pen option
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue